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OBJECTIVE—An impaired ability to sense and appropriately
respond to insulin-induced hypoglycemia is a common and
serious complication faced by insulin-treated diabetic patients.
This study tests the hypothesis that insulin acts directly in the
brain to regulate critical glucose-sensing neurons in the hypo-
thalamus to mediate the counterregulatory response to
hypoglycemia.
RESEARCH DESIGN AND METHODS—To delineate insulin
actions in the brain, neuron-speciﬁc insulin receptor knockout
(NIRKO) mice and littermate controls were subjected to graded
hypoglycemic (100, 70, 50, and 30 mg/dl) hyperinsulinemic (20
mU/kg/min) clamps and nonhypoglycemic stressors (e.g., re-
straint, heat). Subsequently, counterregulatory responses, hypo-
thalamic neuronal activation (with transcriptional marker c-fos),
and regional brain glucose uptake (via
14C-2deoxyglucose auto-
radiography) were measured. Additionally, electrophysiological
activity of individual glucose-inhibited neurons and hypotha-
lamic glucose sensing protein expression (GLUTs, glucokinase)
were measured.
RESULTS—NIRKO mice revealed a glycemia-dependent impair-
ment in the sympathoadrenal response to hypoglycemia and
demonstrated markedly reduced (3-fold) hypothalamic c-fos ac-
tivation in response to hypoglycemia but not other stressors.
Glucose-inhibited neurons in the ventromedial hypothalamus of
NIRKO mice displayed signiﬁcantly blunted glucose responsive-
ness (membrane potential and input resistance responses were
blunted 66 and 80%, respectively). Further, hypothalamic expres-
sion of the insulin-responsive GLUT 4, but not glucokinase, was
reduced by 30% in NIRKO mice while regional brain glucose
uptake remained unaltered.
CONCLUSIONS—Chronically, insulin acts in the brain to regu-
late the counterregulatory response to hypoglycemia by directly
altering glucose sensing in hypothalamic neurons and shifting the
glycemic levels necessary to elicit a normal sympathoadrenal
response. Diabetes 59:2271–2280, 2010
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ntensive insulin therapy markedly increases the risk
of severe hypoglycemia in people with type 1 (1) and
type 2 (2) diabetes. Thus, hypoglycemia is the rate-
limiting step for tight glycemic management in dia-
betic patients. In response to hypoglycemia, glucose
sensors in the central and peripheral nervous system
coordinate efferent autonomic responses resulting in the
release of key counterregulatory hormones—glucagon,
norepinephrine, epinephrine, and cortisol. This coordi-
nated response stimulates hepatic glucose output and
restricts glucose utilization to increase blood glucose
levels. Patients with diabetes often have an impaired
ability to sense and respond to hypoglycemia (3–5) be-
cause several components of the counterregulatory re-
sponse have been shown to be either absent (i.e., fall in
insulin, rise in glucagon) or markedly blunted (i.e., the
sympathoadrenal response) (6,7).
While hypoglycemia is caused by absolute or relative
insulin excess, the role of insulin in regulating the
counterregulatory response is unclear. Studies have
demonstrated that increased insulin levels may augment
(8–11), diminish (12), or not change (13–16) the sympa-
thoadrenal response to hypoglycemia. Given recent
evidence indicating that insulin acts in the brain (17),
some studies have investigated whether insulin’s puta-
tive actions in regulating the counterregulatory re-
sponse might be mediated via actions in the central
nervous system. Again, conﬂicting reports suggest that
insulin may act centrally to enhance (18–20), reduce
(21), or not alter (22) the sympathoadrenal response to
hypoglycemia. If insulin acts in the brain, its likely site
of action is glucose-sensing neurons located in the
ventromedial hypothalamus (VMH) (21,23–26). These
glucose-sensing neurons share metabolic similarities to
other well-characterized glucose-sensing cells (i.e., pan-
creatic -cells), especially with regard to glucose trans-
port and metabolism (27–29). On the basis of the
expression of insulin receptors in the majority of glu-
cosensing neurons in the VMH (30), it is postulated that
brain insulin action may mediate its effects on central
glucose sensing by regulating expression of GLUTs
and/or glucokinase.
In this study, the neuronal speciﬁc insulin-receptor
knockout (NIRKO) mouse model, which chronically lacks
central nervous system (CNS) insulin signaling (17,31),
was used to investigate the role and mechanism by which
brain insulin action regulates central glucose sensing and
the counterregulatory response to hypoglycemia.
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Mice homozygous for the ﬂoxed insulin receptor allele (IR
lox-lox) were bred
with transgenic mice that express Cre recombinase cDNA from the rat nestin
promoter to generate (IR
lox-lox:nestin-Cre
/) NIRKO mice (17). Genotypes
were determined by PCR of tail DNA. Unless otherwise indicated, 2–4-month-
old NIRKO (IR
lox-lox:nestin-Cre
/) and littermate control (control, IR
lox-lox:
nestin-Cre
/) mice were used for these experiments. All mice were housed
on a 12-h light/dark cycle and fed a standard rodent chow (Mouse Diet 9F, PMI
Nutrition International, St. Louis, MO) ad libitum. All procedures were in
accordance with the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and were approved by the Animal Studies
Committee of Washington University.
Hypoglycemic-hyperinsulinemic glucose clamps. Mice anesthetized with
ketamine/xylazine (87 and 13.4 mg/kg i.p.) were implanted with catheters
(MRE 025, Braintree Scientiﬁc Inc., Braintree, MA) into both the right internal
jugular and the left carotid or femoral artery. After a 5–7-day recovery period,
hyperinsulinemic (20 mU/kg/min) hypoglycemic clamps were performed in
5-h fasted, awake, unrestrained, NIRKO and control mice (n  6–9 per group).
To create different degrees of hypoglycemic stress, arterial blood glucose was
measured at 10-min intervals and the rate of intravenous 50% dextrose
infusion was carefully adjusted to create equivalent levels of mild (70 mg/dl),
moderate (50 mg/dl), and severe hypoglycemia (30 mg/dl) as well as a
euglycemic (110 mg/dl) control. High-performance liquid chromatography–
puriﬁed [3-
3H]-glucose tracer (NEN Life Science Products Inc., Boston, MA)
was infused (10 Ci bolus and 0.1 Ci/min) for the assessment of hepatic
glucose production (32). Three blood samples for hepatic glucose production
determination were taken during the basal period and again during the last
0.5 h of the clamp. An additional blood sample was obtained for hormonal
measurements during the basal period and at the end of the clamp.
Brain glucose uptake. Brieﬂy, awake, unrestrained, cannulated NIRKO and
littermate control mice (n  6–9 per group) underwent a 2-h hyperinsulinemic
(40 mU/kg/min) hypoglycemic (30 mg/dl) clamp protocol. At 45 min before the
end of the clamp, a 5 Ci bolus of
14C 2-deoxyglucose was rapidly infused
intravenously and 10 timed arterial blood samples were collected for analysis
of arterial plasma glucose and
14C levels. Isotope concentrations in regions of
interest were measured from 20 m thick coronal serial sections after
exposure to autoradiograph ﬁlm via optical densitometry. Regional glucose
uptake was calculated according to Sokoloff’s equation using rat rate con-
stants, as mice rate constants have not been established (33).
Hypoglycemia-induced c-fos expression. Awake, 5-h fasted NIRKO (n  4)
and littermate controls (n  6) were given a single intraperitoneal injection of
high-dose insulin (3.0–3.5 units/kg) to achieve a consistent and stable hypo-
glycemic insult (30 mg/dl) for 2 h. Euglycemic controls (110 mg/dl, n  4
per group) were given an i.p. injection of saline. After a 2-h duration of
hypoglycemia (or euglycemia), each cryoprotected brain was analyzed for
c-fos expression.
Electrophysiological studies. Male 14–28-day-old NIRKO and littermate
control mice were anesthetized and transcardially perfused with ice-cold
oxygenated perfusion. Sections (350 m) through the hypothalamus were
made on a vibratome (Vibroslice; Camden Instruments). The brain slices were
maintained at 34°C in oxygenated high-Mg
2 low-Ca
2 artiﬁcial cerebrospinal
ﬂuid (ACSF) for 30 min and then transferred to normal oxygenated ACSF for
the remainder of the day. Viable neurons were visualized and studied under
infrared differential-interference contrast microscopy using a Leica DMLS
microscope equipped with a 40 long working-distance water-immersion
objective. Current-clamp recordings (standard whole-cell recording conﬁgu-
ration) from neurons in the VMH were made using an Axopatch 1D ampliﬁer
(Axon Instruments, Foster City, CA) as previously described (34,35). During
recording, brain slices were perfused at 10 ml/min with normal oxygenated
ACSF. Input resistance was calculated from the change in membrane potential
in response to small 500-ms hyperpolarizing pulses (10 to 20 pA) given
every 3 s. The membrane potential response was measured only after the
membrane response to altered extracellular glucose had stabilized, and this
value was compared with controls that were measured immediately before
changing extracellular glucose. Individual glucose-inhibited neurons were
identiﬁed as those neurons that increased their action potential frequency,
membrane potential, and input resistance with decreases in extracellular
glucose from 2.5 to 0.1 mmol/l.
Restraint stress. Awake, 5-h fasted control and NIRKO mice (n  6 per
group) were placed in a mouse restrainer (Braintree Scientiﬁc, Braintree, MA)
for 45 min to induce restraint stress. Cardiovascular parameters were ob-
tained during the basal period and during the last 20 min of restraint stress
using a tail-cuff system (Kent Scientiﬁc Corporation, Torrington, CT). Blood
samples were taken by previously implanted arterial cannula at the beginning
and end of the restraint period to measure plasma epinephrine levels.
Heat stress. Awake control and NIRKO mice (n  6 per group) were exposed
to an ambient temperature of 42°C for 90 min to induce heat stress. Blood
samples were taken at the end of the heat stress period to measure
catecholamines. Subsequently, cryoprotected brains were analyzed for heat
stress–induced c-fos immunostaining.
Western blots. The medial basal hypothalamus, deﬁned anatomically as
posterior to the optic chiasm, anterior to the mammillary body, inferior to the
thalamus, and 1 mm lateral to the midline, was dissected and frozen for
analysis. Homogenized hypothalamic protein extracts (20 g for GLUT1 and
GLUT3; 100 g for GLUT4 and glucokinase) were fractionated by electro-
phoresis on a 10% Bis-Tris Criterion XT (Biorad, Hercules, CA) gel and
subjected to transfer. The following primary antibodies were used: GLUT1
(1:5,000, Chemicon), GLUT3 (1:1,000, Chemicon), GLUT4 (1:1,000, kindly
supplied by Dr. M. Mueckler), glucokinase (1:1,000, Calbiochem). The blots
were developed using a horseradish peroxidase-conjugated secondary anti-
body (1:8,000). Primary antibody binding was detected by enhanced chemilu-
minescence reagents (Perkin Elmer, Wellesley, MA) on ISO-MAX ﬁlms and
quantiﬁed by ImageQuant software analysis (Amersham Pharmacia, Piscat-
away, NJ). An antibody against -actin (1:2,000, Sigma, St. Louis, MO) served
as a loading control.
Immunohistochemistry. Cryoprotected brains were processed for DAB
3,3	-diaminobenzidine peroxidose substrate immunohistochemistry or immu-
noﬂuorescence. Brieﬂy, free-ﬂoating hypothalamic sections (20–30 m)
throughout the VMH/arcuate nucleus (ARC) were taken from 1.46 to 1.82 mm
caudal to bregma, blocked, and incubated overnight at 4°C in primary
antibodies. The following antibody dilutions were used: GLUT4 (1:1,000), c-fos
(1:2000, Ab-5, Calbiochem). For immunoﬂuorescence, goat anti-rabbit Texas
Red (1:200, Molecular Probes) was used as the secondary antibody. Subse-
quently, the sections were mounted on slides using Vectashield Mounting
Medium (Vector Laboratories, Burlingame, CA). For DAB immunohistochem-
istry, immunoreactivity was performed with biotinylated goat anti-rabbit
immunoglobulin G (1:200) using the Elite ABC kit (Vector Laboratories). As a
negative control, alternative sections were incubated without primary anti-
bodies. Regions of interest were identiﬁed using anatomical landmarks (36),
and positively stained cells were counted by a blinded investigator. Four to six
brain sections per mouse were quantiﬁed for statistical purposes.
RT-PCR. Sections (400 m) were taken from brain sections 1.46–1.86 mm
caudal to bregma. Bilateral punch biopsy samples (0.5 mm) from the VMH and
ARC (0.75 mm from the piriform cortex) were collected from NIRKO mice and
littermate controls (n  7–8 per group). The mRNA extracted with Trizol
(Invitrogen Corporation, Carlsbad, CA) was subject to quantitative two-step
RT-PCR performed in triplicate in a ﬂuorescent temperature cycler (GeneAmp
7,700 Sequence Detector, Applied Biosystems) with glucokinase primers
(glucokinase probe 5	-/56-FAM/ACC GCC AAT GTG AGG TCG GCA/3BHQ_1/-
3	; glucokinase reverse 5	-AGC CGG TGC CCA CAA TC-3	; and glucokinase
forward 5	-CCA CAA TGA TCT CCT GCT ACT ATG A-3	). The results were
quantiﬁed after normalizing to rRNA L32mRNA.
Plasma assays. Blood glucose was measured by a glucometer (Becton,
Dickinson and Company, Franklin Lakes, NJ), while plasma glucose was
assayed by the glucose oxidase method and a spectrophotometer (BioTek
Instruments, Inc., Winooski, VT). Radioimmunoassays were performed for
glucagon (LINCO Research, Inc., St. Charles, MO) and corticosterone (ICN
Biomedicals, Inc., Costa Mesa, CA). Insulin was assayed by ELISA (Chrystal
Chem. Inc., Downers Grove, IL). Plasma epinephrine and norepinephrine were
measured with a single isotope derivative (radioenzymatic) method (37).
Statistics. All values are presented as the mean  SEM. Statistical signiﬁ-
cance was set at P 
 0.05, as determined by Student t test.
RESULTS
Brain insulin action is necessary for full sympathoa-
drenal response to hypoglycemia. To characterize the
counterregulatory response to hypoglycemia, a series of
hyperinsulinemic glucose clamps were performed. Blood
glucose was clamped at 110, 70, 50, and 30 mg/dl in control
and NIRKO mice to induce different degrees of hypogly-
cemia (mild  70 mg/dl, moderate  50 mg/dl, and severe
hypoglycemia  30 mg/dl) or no hypoglycemia (euglyce-
mic clamp  110 mg/dl) (Fig. 1). In response to insulin
infusion, plasma insulin levels were similarly elevated in
NIRKO and control mice (Fig. 2A). Severe hypoglycemia
(30 mg/dl) resulted in a sixfold increase in glucagon levels
and 60% increase in corticosterone levels, but these
increases were similar in both groups (Fig. 2B and C).
BRAIN INSULIN ACTION REGULATES GLUCOSE SENSING
2272 DIABETES, VOL. 59, SEPTEMBER 2010 diabetes.diabetesjournals.orgThe epinephrine response was signiﬁcantly impaired in
NIRKO mice during moderate (50 mg/dl) and severe (30
mg/dl) hypoglycemia (Fig. 3A). The epinephrine responses
were highly correlated to glycemia levels in both control
(R
2  0.76) and NIRKO (R
2  0.75) mice but were different
between groups as indicated by a shift in the hypoglyce-
mia–epinephrine response curve (Fig. 3A, inset). Norepi-
nephrine levels trended lower in NIRKO mice during
moderate (50 mg/dl) and severe (30 mg/dl) hypoglycemia,
but the difference did not reach signiﬁcance (Fig. 3B). In
response to the high dose of insulin (20 mU/kg/min),
hepatic glucose production was completely inhibited dur-
ing the hyperinsulinemic clamp at glycemic levels of 100,
70, and 50 mg/dl. During severe hypoglycemia (30 mg/dl),
hepatic glucose production rose signiﬁcantly; however,
the rise in hepatic glucose production was signiﬁcantly
blunted in NIRKO mice (Fig. 3C).
Absent CNS insulin action impairs hypothalamic neu-
ronal activation to hypoglycemia. To assess the brain’s
response to hypoglycemia, c-fos-based functional mapping
was used to demonstrate activated neurons and functional
circuits that respond to hypoglycemic stress (38). Eugly-
cemic (110 mg/dl) controls displayed low c-fos expres-
sion in the hypothalamus (Fig. 4B). In response to insulin-
induced hypoglycemia (31.5  3.1 mg/dl), both NIRKO and
control mice markedly increased c-fos expression within
the paraventricular nucleus (PVN) of the hypothalamus
(Fig. 4A). However, NIRKO animals showed a threefold
impairment in c-fos activation as compared with controls
(control: 99  16 vs. NIRKO: 31  5, P 
 0.01) (Fig. 4B).
Impaired glucose sensing in individual glucose-inhib-
ited neurons. Whole-cell current-clamp recordings were
performed to evaluate the glucose sensitivity of individual
glucose-inhibited neurons in the VMH. As expected for
VMH glucose-inhibited neurons bathed in sufﬁcient 2.5
mmol/l glucose, action potentials in this basal state were
absent in recordings from both control and NIRKO mice.
There were also no group differences in membrane poten-
tial (MP) or input resistance (IR) in 2.5 mmol/l glucose
(control: MP  57  4 mV, IR  1,209  272 M; NIRKO:
MP  59  3 mV, IR  1,016  162 M). Further, no
group differences were observed in glucose-inhibited neu-
rons in response to a maximal glucose decrease from 2.5
to 0.1 mmol/l (not shown). In contrast, glucose-inhibited
neurons in NIRKO mice had a signiﬁcantly impaired
change in membrane potential and input resistance (66
and 80% impairment, respectively) in response to a glu-
cose decrease from 2.5 to 0.5 mmol/l (Fig. 4C and D).
Absent CNS insulin signaling does not inﬂuence re-
sponse to restraint or heat stress. NIRKO and control
mice were subjected to a mild stressor (restraint stress)
and a more profound stressor (heat stress) to evaluate
sympathoadrenal activation in response to glycemia-inde-
pendent stress. In response to milder restraint stress,
plasma epinephrine levels rose similarly twofold in both
littermate controls and NIRKO mice (Fig. 5A). The physi-
ological increased heart rate to restraint stress was also
similar in control and NIRKO mice (Fig. 5B). Heat stress
induced a more pronounced catecholamine elevation than
restraint stress (to levels observed with hypoglycemia),
but the rise in both epinephrine and norepinephrine in
response to heat stress was again not signiﬁcantly different
between groups (Fig. 6C and D). To determine whether
this defect in neuronal activation was unique to hypogly-
cemia, c-fos expression was also assessed in response to
heat stress. Increased c-fos expression was again noted in
the PVN in response to heat stress (Fig. 6A), to levels
observed with hypoglycemia; however, in response to heat
stress, there was no difference in c-fos expression between
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(Fig. 6B).
Abrogated brain insulin action and expression of
hypothalamic glucose sensors. To assess whether CNS
insulin action regulates GLUTs and glucokinase in the
brain, hypothalamic protein and mRNA expression were
assessed. GLUT1 and GLUT3 hypothalamic protein ex-
pression were threefold higher than either GLUT4 or
glucokinase. GLUT1 protein levels in the hypothalamus
were similar in control and NIRKO mice (Fig. 7A and B).
Hypothalamic GLUT3 protein levels in NIRKO mice were
slightly (80.5  9.8% of control) but not signiﬁcantly (P 
0.08) reduced (Fig. 7A and B). Glucokinase protein levels
were also similar in control and NIRKO mice (Fig. 7A and
B). Glucokinase mRNA expression was preferentially ex-
pressed in the VMH and arcuate nucleus, but there was no
difference in expression levels between experimental
groups (Fig. 7C), consistent with the glucokinase protein
expression ﬁndings. Interestingly, insulin-regulated GLUT,
GLUT4, protein levels were signiﬁcantly reduced (68.5 
5.5% of control, P 
 0.05) in the hypothalamus of NIRKO
mice (Fig. 7A and B). To assess regional localization,
immunohistochemistry results demonstrated that GLUT4
protein was highly enriched in the VMH and the ARC of
control mice. In NIRKO mice, GLUT4 protein expression
was markedly reduced in these regions (Fig. 7D). Despite
reductions in GLUT expression in NIRKO mice, regional
brain glucose uptake, as assessed during hyperinsuline-
mic-hypoglycemic clamps, was not different between ex-
perimental groups (Fig. 7E).
DISCUSSION
Insulin’s role in regulating the counterregulatory response
to hypoglycemia is an area of active investigation. Insulin
has been shown to increase (8–11,18–20), diminish
(12,21), and not alter (13–16,22) the sympathoadrenal
response to hypoglycemia. In this study, using a model of
chronic brain insulin receptor deﬁciency, it was demon-
strated that insulin action in the brain 1) regulates the
glucose sensitivity of glucose-sensing neurons in the VMH,
2) regulates hypothalamic neuronal activation uniquely
due to hypoglycemic stress, and 3) modulates the sympa-
thoadrenal response to hypoglycemia by altering the gly-
cemic level required to elicit appropriate sympathoadrenal
responses.
In these studies, a 60% rise in corticosterone was
observed in response to severe hypoglycemia in NIRKO
and control mice (Fig. 2B). Although not well character-
ized in mice, this degree of hypothalamic–pituitary–adre-
nal induced increment in corticosterone is consistent with
other groups (39,40). Contrary to the stimulatory effect of
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in canine models (18,19), these studies in mice demon-
strate that the absence of brain insulin action does not
impair the hypothalamic–pituitary–adrenal axis response
to hypoglycemia.
Reports of insulin action’s in the CNS in modulating the
glucagon response to hypoglycemia are variable, with
studies demonstrating insulin to increase (18,19), decrease
(21), or not effect (20) the glucagon response to hypogly-
cemia. In the current studies, the pancreatic -cell re-
sponse to severe hypoglycemia showed a sixfold increase
in plasma glucagon levels that was not altered by the
absence of CNS insulin receptors in NIRKO mice. Inter-
estingly, although catecholamines stimulate the -cell, the
impaired catecholamine response to hypoglycemia did not
diminish the full glucagon response in NIRKO mice (Fig.
2C). These results indicate that factors other than central
insulin action and systemic catecholamine responses (per-
haps local glycemia, intraislet insulin/zinc, direct innerva-
tions, etc.) are more important mediators of the glucagon
response to hypoglycemia.
The absence of brain insulin receptors resulted in a
signiﬁcantly impaired epinephrine response in NIRKO
mice during moderate (50 mg/dl) and severe (30 mg/dl)
hypoglycemia. However, the absence of brain insulin
signaling did not result in total deﬁciency of hypoglycemic
counterregulation. An epinephrine response of 1,500
pg/ml, which was achieved during moderate hypoglycemia
(50 mg/dl) in controls, was also elicited at a lower blood
glucose level (30 mg/dl) in NIRKO mice (Fig. 3A). Consis-
tent with this ﬁnding, the shift in the hypoglycemia–
epinephrine response curve (Fig. 3A, inset) indicates that,
in the absence of insulin signaling, NIRKO mice needed to
reach lower glycemic levels to appropriately activate their
adrenomedullary response. While insulin infusion sup-
pressed hepatic glucose production during the clamps,
only during severe hypoglycemia (30 mg/dl) was the
counterregulatory response of a sufﬁcient magnitude to
overcome the suppressive effects of insulin and signiﬁ-
cantly increase hepatic glucose production. In NIRKO
mice, however, the counterregulatory-induced stimulation
of hepatic glucose production was signiﬁcantly blunted
during severe hypoglycemia (Fig. 3C), consistent with an
impaired sympathoadrenal response. These ﬁndings indi-
cate that chronic lack of CNS insulin action alters glucose
sensing and/or responsiveness, leading to an impaired
sympathoadrenal response and an impaired ability to
defend against iatrogenic hypoglycemia.
Because the adrenomedullary response to hypoglycemia
was not impaired during mild hypoglycemia in NIRKO
mice, it was speculated that mild (restraint) stress, as
noted by modest elevations in epinephrine levels (Fig. 5A),
might not have been of sufﬁcient magnitude to detect a
differential response between control and NIRKO mice.
However, by achieving comparable epinephrine levels
during severe stress (heat) and severe hypoglycemia (30
mg/dl) and ﬁnding a normal catecholamine response to
heat stress in NIRKO mice, these ﬁndings indicate that
absent CNS insulin signaling does not impair the normal
adrenomedullary response even to severe nonhypoglyce-
mic stress (Fig. 3A, Fig. 6A).
Increased c-fos expression in the PVN has been used as
a marker of transcriptional activity in stress-related neural
circuitry (38,41–43). Expression of c-fos was therefore
measured to determine whether the impaired sympatho-
adrenal response in the NIRKO mice was related to
impaired activation of hypothalamic sensing neurons. Dur-
ing hypoglycemia, increased c-fos expression was predom-
inantly observed in the PVN and not seen in the VMH,
consistent with other studies (44). Hypoglycemia-induced
c-fos activation in the PVN may represent direct activation
in response to hypoglycemia or indirect activation in
response to afferent input from other areas containing
glucose-sensing neurons. Thus, the impaired c-fos activa-
tion in the PVN of NIRKO mice in response to hypoglyce-
mia could represent reduced glucose sensing of PVN
neurons or, given the abundance of insulin receptors in
important VMH glucose-sensing neurons, an indirect re-
duction in afferent inputs from glucose-sensing neurons in
the VMH. Whether this defect indicates impaired direct or
indirect glucose sensing, the reduced c-fos activation in
NIRKO mice was profound and consistent with other
models of impaired glucose sensing and impaired counter-
regulation (43,45). Further, in response to a nonhypogly-
cemic stressor, heat stress increased c-fos expression to a
similar magnitude as observed during severe hypoglyce-
mia (30 mg/dl); however, no difference in heat-induced
c-fos expression was noted between control and NIRKO
mice (Figs. 4 and 6C and D). These results indicate that
NIRKO mice have an intact neuronal circuitry for sensing
and responding to nonhypoglycemic stress; therefore, the
impaired responses to hypoglycemia in the NIRKO mice
appear to be unique to hypoglycemic stress and/or glucose
sensing.
Whole-cell current-clamp recordings of spontaneous
electrical activity were made in individual glucose-inhib-
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sensing neurons in the VMH. While a direct relationship
between glucose-sensing neurons and sympathoadrenal
activation has yet to be deﬁnitively established, it is
noteworthy that the ability of VMH glucose-inhibited neu-
rons to sense a fall in ambient glucose levels is impaired
under several conditions where the sympathoadrenal re-
sponse to hypoglycemia is also impaired (i.e., rats treated
with recurrent hypoglycemia or streptozotocin-induced
diabetes) (35,46,47). In NIRKO mice, the observed im-
paired response of VMH glucose-inhibited neurons to
reductions in glucose levels (Fig. 4C and D) is entirely
consistent with the impaired neuronal (c-fos) activation
(Fig. 4A) and the impaired sympathoadrenal activation
(Fig. 3A). Further, the electrophysiological ﬁndings that
NIRKO glucose-inhibited neurons respond normally to
maximal glucose deprivation (0.1 mmol/l), but impaired
responses at 0.5 mmol/l are consistent with a relative, not
absolute, impairment in glucose sensing. These results
indicate that insulin acts directly in the brain to regulate
the glucose-sensing ability of hypothalamic glucose-inhib-
ited neurons that are critically important and functionally
linked in mediating the sympathoadrenal response to
hypoglycemia. Of particular interest is that glucose-inhib-
ited neurons of NIRKO mice have an impaired ability to
respond to a fall in glucose even in the absence of insulin
administration. Combining these in vitro ﬁndings to the in
vivo ﬁndings suggests that it may not solely be a failure of
insulin to acutely activate its receptor that leads to im-
paired glucose sensing and altered neuronal responses;
rather, we propose that the chronic lack of insulin signal-
ing in NIRKO mice causes long-term adaptations in gene
transcription/transduction (i.e., decrease in GLUT4; see
Fig. 7), leading to impaired glucose sensing. Alternatively,
because neuronal nitric oxide production is required for
glucose-inhibited neurons to sense decreased glucose
(48,49) and insulin enhances nitric oxide production in
VMH glucose-inhibited neurons (48), the chronic lack of
insulin signaling in NIRKO mice may led to impaired
glucose sensing by impairing nitric oxide production. It is
entirely plausible that the chronic actions of insulin may
be mechanistically very different from the acute actions of
insulin in regulating neuronal glucose sensing and the
counterregulatory response to hypoglycemia.
Similar to its well characterized actions in muscle and
fat, insulin-mediated GLUT4 translocation has been dem-
onstrated in neuronal cell lines (50), hippocampus (51),
and hypothalamus (52). GLUT4-mediated glucose sensing
has been speculated to be important at low glucose
concentrations, where insulin-mediated glucose transport
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hypothalamic glucose-sensing neurons (24,26). Indeed,
supporting a glucose-sensing role for insulin receptors and
GLUT4 is their coexpression in up to 75% of glucose-
responsive neurons in the VMH (30). Further, neuronal
GLUT4 has recently been shown to be an important
mediator of hypoglycemic counterregulation and glucose
sensing, as noted in neuronal GLUT4 knockout mice (53).
During hypoglycemia, when glucose transport becomes
rate-limiting, it was speculated that decreased GLUT4
expression and/or deﬁcient insulin action would result in
reduced glucose uptake in critical glucose-sensing regions
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brain glucose uptake during the hyperinsulinemic-hypogly-
cemic clamp (Fig. 7E), indicating that neither deﬁcient
insulin signaling nor the reduced GLUT4 levels altered
glucose uptake in these brain areas. Because brain GLUT4
expression is much lower than other glucose transporters,
it is likely that glucose uptake was primarily regulated by
the more abundant GLUT1 and GLUT3, thus masking any
subtle effect caused by decreased GLUT4. While regional
brain glucose uptake was not altered in NIRKO mice, an
effect of insulin signaling and/or GLUT4 availability on
mediating glucose uptake in individual glucose sensing
neurons cannot be ruled out.
In summary, it is shown that the chronic lack of insulin
receptor signaling in the CNS 1) decreases hypothalamic
GLUT4 expression, 2) attenuates individual hypothalamic
glucose-inhibited neuronal responses to low glucose, 3)
impairs hypothalamic neuronal activation in response to
hypoglycemia, and 4) reduces the sympathoadrenal re-
sponse to hypoglycemia by shifting the glycemic level
necessary to elicit appropriate sympathoadrenal re-
sponses. These defects are speciﬁc for glucose sensing, as
the lack of CNS insulin signaling does not restrict neuronal
activation or the adrenomedullary response to restraint or
heat stress.
It is concluded that insulin acts directly in the brain to
regulate both glucose sensing in hypothalamic neurons
and the counterregulatory response to hypoglycemia. Be-
cause insulin-treated diabetic patients have an impaired
ability to sense and appropriately respond to insulin-
induced hypoglycemia, the mechanisms by which insulin
regulates CNS glucose sensing need to be actively inves-
tigated as research scientists endeavor to supplant insulin-
induced hypoglycemia as the rate-limiting factor in the
glycemic management of diabetes.
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